{"organizations": [], "uuid": "5daff284b9117f98336d7b3307600d949adebed1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-synlogic-doses-first-patient-in-ph/brief-synlogic-doses-first-patient-in-phase-1b-2a-trial-of-synb1020-for-treatment-of-hyperammonemia-in-patients-with-cirrhosis-idUSASC09UEH", "country": "US", "domain_rank": 408, "title": "BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T14:06:00.000+03:00", "replies_count": 0, "uuid": "5daff284b9117f98336d7b3307600d949adebed1"}, "author": "", "url": "https://www.reuters.com/article/brief-synlogic-doses-first-patient-in-ph/brief-synlogic-doses-first-patient-in-phase-1b-2a-trial-of-synb1020-for-treatment-of-hyperammonemia-in-patients-with-cirrhosis-idUSASC09UEH", "ord_in_thread": 0, "title": "BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "synlogic inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "treatment of hyperammonemia in patients with cirrhosis reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News April 2, 2018 / 11:09 AM / Updated 12 minutes ago BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis Reuters Staff 1 Min Read \nApril 2 (Reuters) - Synlogic Inc: \n* SYNLOGIC DOSES FIRST PATIENT IN PHASE 1B/2A TRIAL OF SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH CIRRHOSIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-02T14:06:00.000+03:00", "crawled": "2018-04-02T14:26:18.012+03:00", "highlightTitle": ""}